Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Cardinal Health (NYSE:CAH) will set the price for Navidea Biopharmaceuticals‘ (NYSE Amex:NAVB) cancer drug that could be approved as soon as this summer. While Navidea, developed the drug, called ...

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and ...

A 2018 agreement with Navidea Biopharmaceuticals, subsidiary Macrophage Therapeutics provided for Goldberg's resignation from Navidea, sale of 23.5 million shares of Navidea, and issuance of ...

Larson Brent L, who is EVP, CFO, Treas and Sec’y at Navidea Biopharmaceuticals, sold 12,500 shares at $1.88 on Sept. 2, 2015. Following this transaction, the EVP, CFO, Treas and Sec’y owned 259,737 ...

Navidea Biopharmaceuticals (NYSEMKT:NAVB) puts up a pretty substantial top-line miss for Q3. Lymphoseek sales for the period: $144K. NAVB emphasizes a 600% Q/Q increase in unit dose sales and a ...

Data from Lymphoseek studies to be presented at the Radiological Society of North America Conference (RSNA) and the San Antonio Breast Cancer Symposium Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB ...

Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzheimer’s diagnostic technology as it advances into Phase 3 development. The National Institute of Aging ...

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has entered into an agreement with Nordion ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...